UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

Benzinga Newsdesk www.benzinga.com Positive 66.5%

Neg 0% Neu 0% Pos 66.5%

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.